Trump administration strikes price deal with AstraZeneca

The Trump administration has reached agreement with pharmaceutical company AstraZeneca to lower drug prices across the country.  The agreement requires the company to bring American drug prices in line with the lowest paid by other developed nations, known as most-favored nation price. Nine million Americans are treated by AstraZeneca medications, including those with diabetes, cancer and respiratory conditions. AstraZeneca also announced that it is investing $50 billion in U.S. manufacturing and research and development by 2030 and is building a new facility in Virginia that will create 3,600 jobs. The administration had previously announced an agreement with Pfizer to lower drug prices.